Knowing when to discontinue Temozolomide therapy in responding aggressive pituitary tumors and carcinomas: a systematic review and Padua (Italy) case series

M Padovan, G Cerretti, M Caccese… - Expert Review of …, 2023 - Taylor & Francis
Introduction Pituitary adenomas can show a tendency to grow, despite multimodal treatment.
Temozolomide (TMZ) has been used in the last 15 years in patients with aggressive pituitary …

Silver Nanoparticles From Cassia alata L. Incorporated to Coconut Oil‐Oleogel Based Ointment As An Alternative for Diabetes Mellitus Wound Healing: Optimization, In Vitro …

SA Wiedagdo, AP Febriyanti, S Huda… - …, 2024 - Wiley Online Library
Diabetes mellitus, a widespread chronic illness categorized by elevated blood sugar levels,
poses a significant health burden. This study aimed to synthesize an optimal oleogel formula …

Metastatic pituitary tumors: an institutional case series

AG Yearley, EJ Chalif, S Gupta, JI Chalif, JD Bernstock… - Pituitary, 2023 - Springer
Purpose Pituitary carcinomas are a rare entity that respond poorly to multimodal therapy.
Patients follow a variable disease course that remains ill-defined. Methods We present an …

[HTML][HTML] Intracranial seeding of pituitary neuroendocrine tumor: a case report

C Deng, L Gu, J Sun, M Feng, X Bao - Gland Surgery, 2024 - ncbi.nlm.nih.gov
Background Pituitary neuroendocrine tumors (PitNETs) are predominantly benign, though a
minority may exhibit invasive tendencies. A diagnosis of metastatic PitNETs, in the absence …

[HTML][HTML] Prolactin Secreting Pituitary Carcinoma and the Role of Peptide Receptor Radionuclide Therapy: A Brief Report

N Agarwal, SK Verma, VR Gopinathan… - Neurology …, 2024 - journals.lww.com
Pituitary carcinoma is a rare entity comprising 0.1–0.2% of all pituitary tumors and presents
significant diagnostic and therapeutic challenges. Intraspinal drop metastasis in these …

[HTML][HTML] Metastatic pituitary neuroendocrine neoplasms: A case report of a malignant prolactinoma

I Manique, S Amaral, T Rego, A Coelho… - Clinical Case …, 2024 - ncbi.nlm.nih.gov
Majority of pituitary neoplasms are benign adenomas. However, 30%–45% of pituitary
adenomas can be invasive, and 15% may have an aggressive behavior. 1, 2 This …

[PDF][PDF] Prolattinoma aggressivo con evoluzione in Carcinoma ipofisario: un caso clinico

D Falaguasta, S Garelli, M Mazzucato, F Presotto… - congressoame.com
Gli adenomi ipofisari, prevalentemente prolattinomi, possono manifestarsi in forme
aggressive. Le caratteristiche dei prolattinomi aggressivi sono: tumore radiologicamente …